Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-026-68554-6
Affiliations:
7
Authors:
13
Go to article
Institutions Authors Share
Jiangsu Cancer Hospital, China
5.000000
 0.38
Liyang People's Hospital, China
2.000000
 0.15
Simcere Pharmaceutical Group, China
2.000000
 0.15
China Pharmaceutical University (CPU), China
2.000000
 0.15
Yijishan Hospital of Wannan Medical College, China
1.000000
 0.08
First Affiliated Hospital, AHMU, China
1.000000
 0.08
Interested in Oncology and Carcinogenesis?